87673-89-0

Usage

Chemical class

imidazopyridines

Also known as

SCH39166

Main property

selective dopamine D1-like receptor antagonist

Potential pharmacological effects

on the central nervous system

Potential use

in the treatment of neurological and psychiatric disorders (e.g. schizophrenia, drug addiction)

Other potential properties

analgesic, antipsychotic agent

Used as

a tool compound in studies related to dopamine receptor function and the neurobiology of addiction.

Upstream product

• 87673-86-7 1-(4-Methoxy-phenyl)-2-(1-phenyl-1,4,6,7-tetrahydro-imidazo[4,5-c]pyridin-5-yl)-ethanol 
• 1202800-69-8 1-phenyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridine-5-carboxylic acid tert-butyl ester 
• 272-97-9 Imidazo<4,5-c>pyridin 
• 61532-35-2 1-phenyl-1H-imidazo[4,5-c]pyridine 

Downstream Products

• 1202800-33-6 C₂₅H₂₂N₈O₃ 

Relevant academic research and scientific papers

Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1H-imidazo[4,5-c]pyridin-5(4H)-yl)methanone (JNJ 54166060), a Small Molecule Antagonist of the P2X7 receptor

The synthesis and SAR of a series of 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridine P2X7 antagonists are described. Addressing P2X7 affinity and liver microsomal stability issues encountered with this template afforded methyl substituted 4,5,6,7-tetrahydro-imidazo[4,5-c]pyridines ultimately leading to the identification of 1 (JNJ 54166060). 1 is a potent P2X7 antagonist with an ED50 = 2.3 mg/kg in rats, high oral bioavailability and low-moderate clearance in preclinical species, acceptable safety margins in rats, and a predicted human dose of 120 mg of QD. Additionally, 1 possesses a unique CYP profile and was found to be a regioselective inhibitor of midazolam CYP3A metabolism.

P2X7 MODULATORS

The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.

DIKETO AZOLOPIPERIDINES AND AZOLOPIPERAZINES AS ANTI-HIV AGENTS

Compounds having drug and bio-affecting properties, their pharmaceutical compositions and methods of use are set forth. In particular, diketo fused azolopiperidine and azolopiperazine derivatives that possess unique antiviral activity are provided. These compounds are useful the treatment of HIV and AIDS.